348 related articles for article (PubMed ID: 12422135)
1. New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone.
Funder JW
Am Heart J; 2002 Nov; 144(5 Suppl):S8-11. PubMed ID: 12422135
[No Abstract] [Full Text] [Related]
2. Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.
Hu X; Li S; McMahon EG; Lala DS; Rudolph AE
Mini Rev Med Chem; 2005 Aug; 5(8):709-18. PubMed ID: 16101407
[TBL] [Abstract][Full Text] [Related]
3. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
Moore TD; Nawarskas JJ; Anderson JR
Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
[TBL] [Abstract][Full Text] [Related]
4. [Aldosterone antagonist therapy for chronic heart failure].
Yamamoto T; Yano M
Nihon Naika Gakkai Zasshi; 2005 Feb; 94(2):262-9. PubMed ID: 15768590
[No Abstract] [Full Text] [Related]
5. Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats.
Endemann DH; Touyz RM; Iglarz M; Savoia C; Schiffrin EL
Hypertension; 2004 Jun; 43(6):1252-7. PubMed ID: 15117913
[TBL] [Abstract][Full Text] [Related]
6. Aldosterone target organ protection by eplerenone.
Rudolph AE; Rocha R; McMahon EG
Mol Cell Endocrinol; 2004 Mar; 217(1-2):229-38. PubMed ID: 15134822
[TBL] [Abstract][Full Text] [Related]
7. Eplerenone--a novel selective aldosterone blocker.
Zillich AJ; Carter BL
Ann Pharmacother; 2002 Oct; 36(10):1567-76. PubMed ID: 12243608
[TBL] [Abstract][Full Text] [Related]
8. Recent studies with eplerenone, a novel selective aldosterone receptor antagonist.
McMahon EG
Curr Opin Pharmacol; 2001 Apr; 1(2):190-6. PubMed ID: 11714095
[TBL] [Abstract][Full Text] [Related]
9. Selective aldosterone blockade with eplerenone in patients with congestive heart failure.
Salam AM
Expert Opin Investig Drugs; 2003 Aug; 12(8):1423-7. PubMed ID: 12882627
[TBL] [Abstract][Full Text] [Related]
10. A comparison of the aldosterone-blocking agents eplerenone and spironolactone.
Karagiannis A; Athyros VG; Mikhailidis DP
Clin Cardiol; 2009 Apr; 32(4):230. PubMed ID: 19353701
[No Abstract] [Full Text] [Related]
11. [Aldosterone receptor antagonists in heart failure. Rightly brought back from retirement].
Kolloch R; Offers E
MMW Fortschr Med; 2003 Nov; 145(47):42-4, 47. PubMed ID: 14725033
[TBL] [Abstract][Full Text] [Related]
12. Eplerenone: a selective aldosterone receptor antagonist (SARA).
Delyani JA; Rocha R; Cook CS; Tobert DS; Levin S; Roniker B; Workman DL; Sing YL; Whelihan B
Cardiovasc Drug Rev; 2001; 19(3):185-200. PubMed ID: 11607037
[TBL] [Abstract][Full Text] [Related]
13. New treatment option for heart failure patients: eplerenone.
Southworth MR; Cavallari LH
J Cardiovasc Nurs; 2004; 19(6):390-5. PubMed ID: 15529060
[TBL] [Abstract][Full Text] [Related]
14. [Aldosterone and its antagonists in heart failure].
Lopes ME; Le Corvoisier P; Tabet JY; Su JB; Badoual T; Cachin JC; Merlet P; Castaigne A; Hittinger L
Presse Med; 2003 Jan; 32(2):79-87. PubMed ID: 12653034
[TBL] [Abstract][Full Text] [Related]
15. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker.
Ohtani T; Ohta M; Yamamoto K; Mano T; Sakata Y; Nishio M; Takeda Y; Yoshida J; Miwa T; Okamoto M; Masuyama T; Nonaka Y; Hori M
Am J Physiol Regul Integr Comp Physiol; 2007 Feb; 292(2):R946-54. PubMed ID: 17023667
[TBL] [Abstract][Full Text] [Related]
16. Eplerenone: a selective aldosterone blocker.
Stier CT
Cardiovasc Drug Rev; 2003; 21(3):169-84. PubMed ID: 12931252
[TBL] [Abstract][Full Text] [Related]
17. Eplerenone in the treatment of chronic heart failure.
Krum H; Liew D
Expert Rev Cardiovasc Ther; 2004 May; 2(3):315-20. PubMed ID: 15151479
[TBL] [Abstract][Full Text] [Related]
18. The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure.
Hameedi A; Chadow HL
Curr Hypertens Rep; 2000 Aug; 2(4):378-83. PubMed ID: 10981173
[TBL] [Abstract][Full Text] [Related]
19. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
[TBL] [Abstract][Full Text] [Related]
20. [Cardioprotective effect of aldosterone antagonists for ventricular remodeling].
Tatsumi T; Matsubara H
Nihon Rinsho; 2006 Jul; 64 Suppl 5():524-9. PubMed ID: 16897886
[No Abstract] [Full Text] [Related]
[Next] [New Search]